Whoever sells in the $15's will need to find a better buy. This stock is going to $20 and soon. Listen to the pres. It is more informative than the earnings CC. Zegerid gross margins are 90%. Uceris is expected to be a $300 million product. Ruconst to be filed for acute HAE in 2nd quarter. Meeting with FDA to talk about potential for proph HAE and acute pancreatitis later in the year. Summary, no company out there with nice portfolio of products (small molecule and biologics). Plan to bring in new products!!